Search
Protein S human
go.drugbank.com/drugs/DB13149ApprovedInvestigationalProtein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade.
Prophylaxis of Thromboembolic event
go.drugbank.com/conditions/DBCOND0024073Witch hazel
go.drugbank.com/drugs/DB11111ApprovedInvestigationalNutraceuticalProducts: Mefacory Super Deep Cleansing Foa m, Mefactory Super Deep Cleansing Foa mAmlodipine
go.drugbank.com/drugs/DB00381ApprovedInvestigationalThe option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label]. … Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_.
Mixtures: LOSAMLO 50MG/5MG FTA, LOSAMLO 50MG/5MG FTAProducts: NORVASC 5MG FTA, Nra-amlodipineIbandronate
go.drugbank.com/drugs/DB00710ApprovedInvestigational[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]
Products: BONVIVA 150MG FTAMetformin
go.drugbank.com/drugs/DB00331ApprovedInvestigational[A36559] Metformin was first approved in Canada in 1972,[A36552] and received subsequent FDA approval in the US in 1995.[L12207]
Mixtures: Nra-sitagliptin/metformin, Nra-sitagliptin/metforminProducts: METFORMIN RATIO 500MG FTA, METFORMIN RATIO 850MG FTACoagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalCoagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors
Prophylaxis of Venous thrombosis
go.drugbank.com/conditions/DBCOND0022148Coagulation Factor IX Human
go.drugbank.com/drugs/DB13152ApprovedInvestigationalFactor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.
Ondansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawnHaving been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. … [L5221] The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation.
Products: ONDANSETRON STADA 4 MG FTA, ONDANSETRON STADA 8 MG FTA